Brenton Flynn, Motley Fool health care bureau chief, discusses AbbVie. Like other pharmaceutical companies, this company serves a non-cyclical market of consumers that aren't very price-conscious. He then addresses specific advantages that AbbVie enjoys, naming three reasons to buy the stock:
Humira's pipeline -- AbbVie has a tremendous opportunity to serve hepatitis C patients, of whom there are 170 million worldwide.
Concerns about Humira are overdone. Humira is a biologic, which is more difficult to copy than other small molecule drugs.
AbbVie has one of the top dividends among big pharma, sporting a 4% yield.
Follow along in the video below to learn more about each of these reasons you might consider buying AbbVie for your portfolio.
In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.
The article 3 Reasons to Buy AbbVie Today originally appeared on Fool.com.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.